Figure 5. Antitumor activity of ciglitazone administered as monotherapy in athymic mice bearing T24 and RT4 bladder cancer xenografts.

Mice were inoculated subcutaneously with exponentially growing T24 and RT4 bladder cancer cells (5×10⁶ cells). When tumor size reached 40 mm³ in volume, mice were randomly divided into control and treated groups (n = 10). Intraperitoneal injections of ciglitazone were weekly administered at a dose of 15 mg/kg during three weeks. Control animals received only saline vehicle following an identical schedule. (A) The growth tumor curves were determined by measuring the tumor volume. *P<0.05, significant differences compared with untreated animals with the use of two-way ANOVA test (evaluation of the tumor volume development over time) ; **P<0.05, significant differences between control and treated mice at each post-graft time with the use of two-tailed unpaired Student's t test. (B) Immunohistochemical staining of representative paraffin-embedded sections of tumors from untreated or ciglitazone-treated mice. Sections were fixed and stained for Ki-67 and active caspase 3. Each panel is representative of 5 sections for each of ten tumors from control and ciglitazone-treated mice. Original magnification, ×20.